Preventing and Minimizing Risks Associated with Antituberculosis Medicines to Improve Patient Safety
(2013; 92 pages)

Systems for Improved Access to Pharmaceuticals and Services. 2013. Preventing and Minimizing Risks Associated with Antituberculosis Medicines to Improve Patient Safety. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health.

Abstract
Tuberculosis (TB) is re-emerging as a major threat to global health, due to its co-morbidity with other diseases and the emergence of drug-resistant forms of TB. In 2011, TB caused 1.4 million deaths, including 430,000 among people who were HIV-positive, reflecting the substantial challenges of TB/HIV co-infection. Successfully combating the TB epidemic requires expanding access to treatment, improving management of drug-resistant TB, and integrating services for TB and HIV. To help patients complete their full course of TB treatment, the United States Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program created a guide for national tuberculosis programs (NTP) on how to minimize medicine risks. Titled “Preventing and Minimizing Risks Associated with Antituberculosis Medicines to Improve Patient Safety”, the guide offers insights into planning and implementing risk reduction strategies in the treatment of TB.
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014